Comparative Pharmacology
Head-to-head clinical analysis: CO LAV versus HALFLYTELY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO LAV versus HALFLYTELY.
CO-LAV vs HALFLYTELY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
PEG 3350 is an osmotic agent that causes water retention in the colon, leading to bowel evacuation. Electrolytes (sodium sulfate, potassium chloride, magnesium sulfate, sodium bicarbonate) prevent significant electrolyte shifts.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
Oral: 1 liter (provided as powder for reconstitution) administered at a rate of 240 mL every 10 minutes until rectal effluent is clear or 4 liters total is consumed. Typically given as split-dose: half the volume the evening before and half the morning of colonoscopy.
None Documented
None Documented
Unknown
Not applicable; PEG 3350 is not significantly absorbed and does not have a systemic half-life. The colon transit time is approximately 1 hour after ingestion.
CO-LAV is not a recognized drug. Please check the drug name.
Primarily fecal elimination of unabsorbed PEG 3350; negligible systemic absorption <0.06%. Electrolytes are excreted renally and fecally.
Category C
Category C
Laxative/Bowel Evacuant
Laxative